imalumab imalumab imalumab (bax69) is an experimental monoclonal antibody against macrophage inhibitory factor (mif), a cytokine known to exacerbate tumor growth. and as of january 2017 it is being tested in phase iia clinical trials for metastatic colorectal cancer. it was developed by cytokine pharmasciences and baxalta, which was purchased by shire pharmaceuticals. imalumabmonoclonal antibodytype?clinical dataother namesbax69legal statuslegal status investigational identifierscas number1430205-07-4unii22f97pc79g a phase i/ii trial in patients with malignant ascites was terminated in 2016.